Synthesis, antileishmanial activity and QSAR study of (1,3,4-thiadiazol-2-ylthio) acetamides derived from 5-nitrofuran
Abstract A novel series of (1,3,4-thiadiazol-2-ylthio)acetamides derived from 5-nitrofuran were synthesized and evaluated against extracellular promastigotes of Leishmania major. The most potent anti-promastigote compounds were also evaluated in vitro against intracellular amastigotes. All compounds showed better activity than standard drug Glucantime. The most potent compounds against the promastigotes were found to be N-(3,4-dimethoxyphenethyl)-2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylthio) acetamide (5q) and 2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylthio)-N-propylacetamide (5r) with $ IC_{50} $ values less than 20 µM. Although, the cytotoxic evaluation of target compounds against mouse peritoneal macrophages demonstrated that these series of compounds have cytotoxicity at concentrations higher than 50 µM, but most of them exhibited antileishmanial activity at non-cytotoxic concentrations. QSAR study indicated that 2D-autocorrelation and topological descriptors are influential parameters in the antileishmanial activity..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Medicinal chemistry research - 24(2014), 2 vom: 29. Juli, Seite 891-900 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vosooghi, Mohsen [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
1,3,4-Thiadiazole |
|---|
| Anmerkungen: |
© Springer Science+Business Media New York 2014 |
|---|
| doi: |
10.1007/s00044-014-1155-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2096104785 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2096104785 | ||
| 003 | DE-627 | ||
| 005 | 20230331232639.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230331s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00044-014-1155-1 |2 doi | |
| 035 | |a (DE-627)OLC2096104785 | ||
| 035 | |a (DE-He213)s00044-014-1155-1-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q VZ |
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Vosooghi, Mohsen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthesis, antileishmanial activity and QSAR study of (1,3,4-thiadiazol-2-ylthio) acetamides derived from 5-nitrofuran |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media New York 2014 | ||
| 520 | |a Abstract A novel series of (1,3,4-thiadiazol-2-ylthio)acetamides derived from 5-nitrofuran were synthesized and evaluated against extracellular promastigotes of Leishmania major. The most potent anti-promastigote compounds were also evaluated in vitro against intracellular amastigotes. All compounds showed better activity than standard drug Glucantime. The most potent compounds against the promastigotes were found to be N-(3,4-dimethoxyphenethyl)-2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylthio) acetamide (5q) and 2-(5-(5-nitrofuran-2-yl)-1,3,4-thiadiazol-2-ylthio)-N-propylacetamide (5r) with $ IC_{50} $ values less than 20 µM. Although, the cytotoxic evaluation of target compounds against mouse peritoneal macrophages demonstrated that these series of compounds have cytotoxicity at concentrations higher than 50 µM, but most of them exhibited antileishmanial activity at non-cytotoxic concentrations. QSAR study indicated that 2D-autocorrelation and topological descriptors are influential parameters in the antileishmanial activity. | ||
| 650 | 4 | |a Antileishmanial activity | |
| 650 | 4 | |a 1,3,4-Thiadiazole | |
| 650 | 4 | |a 5-Nitrofuran | |
| 650 | 4 | |a QSAR study | |
| 700 | 1 | |a Sabourian, Reyhaneh |4 aut | |
| 700 | 1 | |a Tahghighi, Azar |4 aut | |
| 700 | 1 | |a Mahdavi, Mohammad |4 aut | |
| 700 | 1 | |a Emami, Saeed |4 aut | |
| 700 | 1 | |a Razmi, Sepideh |4 aut | |
| 700 | 1 | |a Kabudanian Ardestani, Sussan |4 aut | |
| 700 | 1 | |a Safavi, Maliheh |4 aut | |
| 700 | 1 | |a Foroumadi, Parham |4 aut | |
| 700 | 1 | |a Kaveh, Sara |4 aut | |
| 700 | 1 | |a Khoshneviszadeh, Mehdi |4 aut | |
| 700 | 1 | |a Edraki, Najmeh |4 aut | |
| 700 | 1 | |a Shafiee, Abbas |4 aut | |
| 700 | 1 | |a Foroumadi, Alireza |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicinal chemistry research |d Springer US, 1991 |g 24(2014), 2 vom: 29. Juli, Seite 891-900 |h Online-Ressource |w (DE-627)490223427 |w (DE-600)2191978-1 |w (DE-576)262493225 |x 1554-8120 |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2014 |g number:2 |g day:29 |g month:07 |g pages:891-900 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00044-014-1155-1 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_32 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_70 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_90 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_100 | ||
| 912 | |a GBV_ILN_101 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_120 | ||
| 912 | |a GBV_ILN_138 | ||
| 912 | |a GBV_ILN_150 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_152 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_187 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_370 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_636 | ||
| 912 | |a GBV_ILN_702 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2007 | ||
| 912 | |a GBV_ILN_2008 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2015 | ||
| 912 | |a GBV_ILN_2020 | ||
| 912 | |a GBV_ILN_2021 | ||
| 912 | |a GBV_ILN_2025 | ||
| 912 | |a GBV_ILN_2026 | ||
| 912 | |a GBV_ILN_2027 | ||
| 912 | |a GBV_ILN_2031 | ||
| 912 | |a GBV_ILN_2034 | ||
| 912 | |a GBV_ILN_2037 | ||
| 912 | |a GBV_ILN_2038 | ||
| 912 | |a GBV_ILN_2039 | ||
| 912 | |a GBV_ILN_2044 | ||
| 912 | |a GBV_ILN_2048 | ||
| 912 | |a GBV_ILN_2049 | ||
| 912 | |a GBV_ILN_2055 | ||
| 912 | |a GBV_ILN_2057 | ||
| 912 | |a GBV_ILN_2059 | ||
| 912 | |a GBV_ILN_2061 | ||
| 912 | |a GBV_ILN_2064 | ||
| 912 | |a GBV_ILN_2065 | ||
| 912 | |a GBV_ILN_2068 | ||
| 912 | |a GBV_ILN_2070 | ||
| 912 | |a GBV_ILN_2086 | ||
| 912 | |a GBV_ILN_2088 | ||
| 912 | |a GBV_ILN_2093 | ||
| 912 | |a GBV_ILN_2106 | ||
| 912 | |a GBV_ILN_2107 | ||
| 912 | |a GBV_ILN_2108 | ||
| 912 | |a GBV_ILN_2110 | ||
| 912 | |a GBV_ILN_2111 | ||
| 912 | |a GBV_ILN_2112 | ||
| 912 | |a GBV_ILN_2113 | ||
| 912 | |a GBV_ILN_2116 | ||
| 912 | |a GBV_ILN_2118 | ||
| 912 | |a GBV_ILN_2119 | ||
| 912 | |a GBV_ILN_2122 | ||
| 912 | |a GBV_ILN_2129 | ||
| 912 | |a GBV_ILN_2131 | ||
| 912 | |a GBV_ILN_2143 | ||
| 912 | |a GBV_ILN_2144 | ||
| 912 | |a GBV_ILN_2147 | ||
| 912 | |a GBV_ILN_2148 | ||
| 912 | |a GBV_ILN_2152 | ||
| 912 | |a GBV_ILN_2153 | ||
| 912 | |a GBV_ILN_2188 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2232 | ||
| 912 | |a GBV_ILN_2336 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_2470 | ||
| 912 | |a GBV_ILN_2474 | ||
| 912 | |a GBV_ILN_2507 | ||
| 912 | |a GBV_ILN_2522 | ||
| 912 | |a GBV_ILN_2548 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4046 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4242 | ||
| 912 | |a GBV_ILN_4246 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4251 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4326 | ||
| 912 | |a GBV_ILN_4333 | ||
| 912 | |a GBV_ILN_4334 | ||
| 912 | |a GBV_ILN_4335 | ||
| 912 | |a GBV_ILN_4336 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4393 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2014 |e 2 |b 29 |c 07 |h 891-900 | ||